Xenetic Biosciences Extends Collaboration with Scripps Research

Xenetic Biosciences, Inc., a biopharmaceutical company, has announced the extension of its collaboration with The Scripps Research Institute. Effective November 1, 2025, the extension focuses on the development of Xenetic's systemic DNase I candidate, XBIO-015. The partnership aims to advance research into combining DNase I with CAR-T cell therapies for various cancers.

Preclinical studies led by Dr. Alexey Stepanov at Scripps have shown promising results in reducing tumor burden and improving survival rates by enhancing CAR-T cell efficacy. This is achieved by degrading neutrophil extracellular traps (NETs), thereby improving the tumor microenvironment.

James Parslow, Xenetic's Interim CEO, highlighted the importance of the collaboration and its potential to improve patient outcomes. The company is preparing for a Phase 1 clinical trial targeting pancreatic and other solid tumors.